Literature DB >> 23585143

Clinical inertia in poorly controlled elderly hypertensive patients: a cross-sectional study in Spanish physicians to ascertain reasons for not intensifying treatment.

Vicente Gil-Guillén1, Domingo Orozco-Beltrán, Concepción Carratalá-Munuera, Emilio Márquez-Contreras, Ramón Durazo-Arvizu, Richard Cooper, Salvador Pertusa-Martínez, Salvador Pita-Fernandez, Diego González-Segura, José Luis Martin-de-Pablo, Vicente Pallarés, Antonio Fernández, Josep Redón.   

Abstract

BACKGROUND: Clinical inertia, the failure of physicians to initiate or intensify therapy when indicated, is a major problem in the management of hypertension and may be more prevalent in elderly patients. Overcoming clinical inertia requires understanding its causes and evaluating certain factors, particularly those related to physicians.
OBJECTIVE: The objective of our study was to determine the rate of clinical inertia and the physician-reported reasons for it.
METHODS: An observational, cross-sectional, multi-center study was carried out in a primary care setting. We included 512 physicians, with a consecutive sampling of 1,499 hypertensive patients with clinical inertia. MAIN OUTCOME MEASURE: Clinical inertia was defined when physicians did not modify treatment despite knowing that the therapeutic target had not been reached. Clinical inertia was considered to be justified (JCI) when physicians provided an explanation for not intensifying treatment and as not justified (nJCI) when no reasons were given.
RESULTS: JCI was observed in 30.1 % (95 % CI 27.8-32.4) of patients (n = 451) and nJCI in 69.9 % (95 % CI 67.6-72.2) (n = 1,058). JCI was associated with higher blood pressure (BP) values (both systolic and diastolic) and diabetes (p = 0.012) than nJCI. nJCI was associated with patients having an isolated increase of systolic or diastolic or high borderline BP values or cardiovascular disease.
CONCLUSION: Physicians provided reasons for not intensifying treatment in poorly controlled patients in only 30 % of instances. Main reasons for not intensifying treatment were borderline BP values, co-morbidity, suspected white coat effect, or perceived difficulty achieving target. nJCI was associated with high borderline BP values and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23585143     DOI: 10.1007/s40256-013-0025-4

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  7 in total

1.  Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care.

Authors:  Peter Hayes; Monica Casey; Liam G Glynn; Gerard J Molloy; Hannah Durand; Eoin O'Brien; Eamon Dolan; John Newell; Andrew W Murphy
Journal:  Br J Gen Pract       Date:  2018-05-08       Impact factor: 5.386

2.  Predicting changes in hypertension control using electronic health records from a chronic disease management program.

Authors:  Jimeng Sun; Candace D McNaughton; Ping Zhang; Adam Perer; Aris Gkoulalas-Divanis; Joshua C Denny; Jacqueline Kirby; Thomas Lasko; Alexander Saip; Bradley A Malin
Journal:  J Am Med Inform Assoc       Date:  2013-09-17       Impact factor: 4.497

Review 3.  Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison.

Authors:  Martin J Wolley; Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

4.  Development of a complex intervention to promote appropriate prescribing and medication intensification in poorly controlled type 2 diabetes mellitus in Irish general practice.

Authors:  Mark E Murphy; Molly Byrne; Atieh Zarabzadeh; Derek Corrigan; Tom Fahey; Susan M Smith
Journal:  Implement Sci       Date:  2017-09-16       Impact factor: 7.327

5.  Supporting care for suboptimally controlled type 2 diabetes mellitus in general practice with a clinical decision support system: a mixed methods pilot cluster randomised trial.

Authors:  Mark E Murphy; Jenny McSharry; Molly Byrne; Fiona Boland; Derek Corrigan; Paddy Gillespie; Tom Fahey; Susan M Smith
Journal:  BMJ Open       Date:  2020-02-12       Impact factor: 2.692

6.  Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes.

Authors:  Sanjoy K Paul; Kerenaftali Klein; Brian L Thorsted; Michael L Wolden; Kamlesh Khunti
Journal:  Cardiovasc Diabetol       Date:  2015-08-07       Impact factor: 9.951

7.  Supporting general practitioner-based care for poorly controlled type 2 diabetes mellitus (the DECIDE study): feasibility study and protocol for a pilot cluster randomised controlled trial.

Authors:  Mark E Murphy; Molly Byrne; Fiona Boland; Derek Corrigan; Paddy Gillespie; Tom Fahey; Susan M Smith
Journal:  Pilot Feasibility Stud       Date:  2018-10-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.